This guidance replaces NICE technology appraisal guidance 237 (published in November 2011). For details see About this guidance.
1.1 Ranibizumab is recommended as an option for treating visual impairment due to diabetic macular oedema only if:
the eye has a central retinal thickness of 400 micrometres or more at the start of treatment and
the manufacturer provides ranibizumab with the discount agreed in the patient access scheme revised in the context of this appraisal.
1.2 People currently receiving ranibizumab for treating visual impairment due to diabetic macular oedema whose disease does not meet the criteria in 1.1 should be able to continue treatment until they and their clinician consider it appropriate to stop.